Breakthrough antimalarial drug delivery system using mesoporous silica nanoparticles

March 26, 2018, Kumamoto University
Kumamoto University researchers found that using MCM-41 as a drug delivery system for malaria treatment produced a highly efficient treatment in animals. Clinical trials are planned in the near future. Credit: Shinya Hayami

Drug delivery systems (DDSs) control the dosage and timing of drugs. Numerous DDS studies have been conducted, but most have focused on treatments for cancer. New research from Kumamoto University uses a DDS to treat malaria.

The existing treatment for malaria is taken orally and has three main problems: (1) most are broken down in the stomach, (2) the drugs have strong side effects, and (3) the medicine stays in the body for only a short time. These issues have resulted in malaria treatments that were not particularly effective.

MCM-41 is a porous silica material with a pore size of two to 30 nm. It can incorporate drugs into its pores, which makes it a useful material for DDS applications. A research group headed by Prof. Shinya Hayami from Kumamoto University, Japan, believed that MCM-41 could be used as a DDS for antimalarial drugs. To test their theory, they created a new DDS by combining the antimalarial drugs artesunate and quinine with MCT-41 and performed in vitro and in vivo experiments. They found:

  1. The release time of the antimalarial medicine became very long, one week or longer, an improvement from the standard medication time.
  2. Compared to ingesting artesunate or quinine, the new DDS increased treatment efficiency by 20 and 240 times respectively in animal experiments. (As defined in this study, the therapeutic efficiency is 50 percent of the effective dose (ED50), and is used as an index of strength. The smaller the value of ED50, the greater the action of the drug. In other words, if an effect is obtained with a small amount of a drug, the treatment efficiency is high.)
  3. MCM-41 itself is non-toxic and inactive. A DDS using MCM-41 is expected to have very weak side effects.

"Using this DDS for antimalarial drugs has introduced a new possibility for highly efficient for the first time," said Professor Shinya Hayami. "We expect that it will be put to practical use in areas where malaria is still necessary. Now, we are planning to develop clinical trials for antimalarial drugs as well as new DDSs for other drugs like anti-HIV medications."

Explore further: Multidrug resistant genetic factors in malaria parasites

More information: Saliu Alao Amolegbe et al, Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance, Scientific Reports (2018). DOI: 10.1038/s41598-018-21351-8

Related Stories

Multidrug resistant genetic factors in malaria parasites

January 3, 2018

NUS scientists in collaboration with researchers from Norvatis have discovered two genetic markers in Plasmodium falciparum, the deadliest malaria parasite that can cause it to develop resistance against a new antimalarial ...

Scientists find new antimalarial drug targets

February 20, 2018

Researchers have discovered crucial new processes that allow malaria parasites to escape red blood cells and infect other cells, offering potential new treatment targets. The team are already working with pharmaceutical companies ...

Potential new anti-malarial drug identified

February 6, 2014

A significant milestone in the development of a potential new antimalarial medicine has been reached by scientists at the University of Dundee, in partnership with the Medicines for Malaria Venture (MMV).

Malaria: Drug candidate may reduce spread of the parasite

September 6, 2017

Significant headway has been made in controlling malaria. However, two vexing problems remain: currently available treatments are unable to block transmission of the parasite that causes the disease, and the parasite often ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.